Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-869 plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in second-line advanced colorectal cancer
2007-007081-38Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- Sep 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of linifanib, bevacizumab, oxaliplatin, fluorouracil and folinic acid in colorectal cancer (CRC) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: progression-free survival. Started Sep 2008; status: completed.
02
Drugs
linifanibbevacizumaboxaliplatinfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2007-007081-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007081-38.